List the top 2-3 takeaways from your breakout discussions. Please list your group number in your response.

| Clear need for program/portfolio level strategy - Broad sources of data that can inform the strategy. Move from high level data to more local data - community and patients | Group 3 Integrated approach re measuring clinical trial value and taking it back to clinical care. Ability to measure demographic data. Establish a baseline regardless of organizational size. Measure PROM/experience/engagement | Group 2: Community and Patient Engagement
1. Two separate rows: Community Infrastructure and Patient Engagement
2. Under Infrastructure: include how the patient experience informs, identifies stakeholders, generating baselines (complex, varies), and this is an iterative learning process.
3. Current sponsor focus. Add perspectives for sites, academia, advocacy, etc - all partners need to know how/when to add input. | Group 3: Measure geographic participation/distribution. Measuring retention and enrollment, therapeutic and non-therapeutic and across therapeutic areas. |